Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5824527 | Clinical Therapeutics | 2015 | 12 Pages |
Abstract
Based on the findings from this study in patients with opioid dependence, the higher-bioavailability BNX sublingual tablet formulation was noninferior to both generic buprenorphine (induction) and BNX film (stabilization). These findings suggest that BNX sublingual tablets are an efficacious and well-tolerated option for induction and early stabilization treatment of opioid dependence. ClinicalTrials.gov identifier: NCT01908842.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Erik W. MD, Peter MD, Michael MD, on behalf of the 006 Study Investigators on behalf of the 006 Study Investigators,